FDA Approves Bayer’s Advanced Prostate Cancer Drug
Submitted by Gunraj Sandhu on Thu, 05/16/2013 - 13:10
Bayer's treatment for prostate cancer, Xofigo, has been granted approval by the U. S. regulators. The treatment has been approved just three months after it was assigned a priority review.
The US Food and Drug Administration has given a nod for the injection to be used in men with symptomatic late-stage castration-resistant prostate cancer that has spread to bones but nowhere else.
Wrigley Announces Suspension of Caffeinated Chewing Gum Sales
Submitted by Gunraj Sandhu on Fri, 05/10/2013 - 13:17
On Wednesday, it has been announced by Chewing gum maker Wrigley that the production, marketing as well as sale of Alert, its new caffeinated product, is being suspended by it.
It has been found that a new regulation has been framed by the US Food and Drug Administration (FDA) on caffeinated food and drinks. It is a week following the same that Wrigley's North American president, Casey Keller, made the announcement.
FDA Approves Combination Drug for Lowering Cholesterol
Submitted by Kanika Mehta on Sat, 05/04/2013 - 12:46
A recent report has bagged something good for people with high cholesterol levels. On Friday, a combination drug meant for lowering a patient's cholesterol has got approval from the Food and Drug Administration.
New Caffeinated Gum Prompts FDA to Look into Impact of Caffeinated Products
Submitted by Kanika Mehta on Wed, 05/01/2013 - 10:14
The US Food and Drug Administration (FDA) is now carrying out investigation into impact of caffeinated products on children and adolescents. The move is prompted after Wrigley introduced new caffeinated gum into the market.
FDA Refuses Manufacturing of Generic Version of OxyContin
Submitted by Kanika Mehta on Wed, 04/17/2013 - 13:14
Call it a major win for Purdue Pharma, OxyContin's manufacturer, as the Food and Drug Administration has announced that it give green signal to generic versions of OxyContin.
Palbociclib Named Breakthrough Therapy by FDA
Submitted by Kanika Mehta on Thu, 04/11/2013 - 12:11
The United States Food and Drug Administration (FDA) has recently named Palbociclib as a Breakthrough Therapy for treatment of breast cancer.
The drug is manufactured by the pharmaceutical firm Pfizer and is an investigational, oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6. These are two closely linked kinases that trigger tumor cell progression during phase G1 and S in the cell cycle.
FDA Approves Morning Sickness Pill Banned 30 Years Ago
Submitted by Latika Sharma on Tue, 04/09/2013 - 10:25
A drug, Bendectin, meant to treat morning sickness was banned by the US Food and Drug Administration (USFDA) some three decades ago. It now has been found that the same drug, but with a different named known as Diclegis has been approved by the USFDA.
